+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Highs and Lows of Stem Cell Therapies: Off- The-Shelf Solutions

  • ID: 4895943
  • Report
  • December 2019
  • Region: Global
  • 25 pages
  • BCC Research
1 of 3

FEATURED COMPANIES

  • Athersys Inc.
  • Caladrius Biosciences
  • Fate Therapeutics Inc.
  • Gamida Cell Ltd.
  • Orgenesis Inc.
  • Sangamo Therapeutics Inc.
  • MORE
The Report Includes:
  • An overview of recent advances in stem cell therapies and coverage of potential stem cells used for regenerative advanced therapies
  • Discussion on role of genomic and epigenomics manipulations in generating safe and effective treatment options
  • Identification of autologous and allogeneic cells and their usage in creating advanced therapy medical products (ATMPs)
  • Information on 3D cell culture and discussion on advances in gene editing and gene programming techniques such as CRIPSR/Cas9, TALEN, and ZINC fingers
  • Insights into commercial and regulatory landscape, and evaluation of challenges and opportunities for developing autologous and allogenic “off the shelf” solutions
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Athersys Inc.
  • Caladrius Biosciences
  • Fate Therapeutics Inc.
  • Gamida Cell Ltd.
  • Orgenesis Inc.
  • Sangamo Therapeutics Inc.
  • MORE
Chapter 1 Sources and Characteristics of Stem Cells
  • Introduction
Chapter 2 New Technologies Driving Stem Cell Development
  • Advances in Cell Culture
  • Advances in Isolation Technologies
  • Advances in Genome Manipulation
Chapter 3 Safety, Efficacy and Logistical Challenges
  • Toxicity-Related Treatment Issues
  • Logistical Challenges
Chapter 4 Off-the-Shelf Solutions
  • Expanding the Course of Stem Cells
  • More Precise Genomic Manipulation of Cells
  • Reduction in Cell-to-Cell Variation
  • Improved Shelf Life
Chapter 5 Companies and Technologies to Watch
  • Athersys Inc.
  • BrainStorm Cell Therapeutics Inc.
  • Caladrius Biosciences
  • Cellular Biomedicine Group Inc.
  • Fate Therapeutics Inc.
  • Gamida Cell Ltd.
  • International Stem Cell Corporation
  • Orgenesis Inc.
  • Pluristem Therapeutics Inc.
  • Sangamo Therapeutics Inc.
  • TheraCell Inc.
  • ThermoGenesis Holdings
  • Vericel Corporation
  • VistaGen Therapeutics Inc.
  • Zelluna Immunotherapy Inc.
  • Analyst’s Credentials
  • Related Reports
Chapter 6 References

List of Tables
Table 1: Stem Cell Sources
Table 2: Comparison of Stem Cells
Table 3: Stem Cell Types Versus Cell Properties
Table 4: Recent Advances in Genome Modulation Technologies
Table 5: FDA-Approved Cell-Based Therapies
Table 6: Acute and Delayed Adverse Events Associated with Proven and Unproven Stem Cell-Based Interventions
Table 7: Companies Leading the Field in Cell-Based Therapies

List of Figures
Figure 1: Stem Cell Sources
Figure 2: Two-Dimensional Versus Three-Dimensional Cell Culture
Figure 3: Schematic of Approaches Used for Three-Dimensional Stem Cell Culture
Figure 4: Patient Management Strategies to Decrease Side Effects Related with CAR-T Cell Therapy
Note: Product cover images may vary from those shown
3 of 3
  • Athersys Inc.
  • Brainstorm Cell Therapeutics Inc.
  • Caladrius Biosciences
  • Cellular Biomedicine Group Inc.
  • Fate Therapeutics Inc.
  • Gamida Cell Ltd.
  • International Stem Cell Corporation
  • Orgenesis Inc.
  • Pluristem Therapeutics Inc.
  • Sangamo Therapeutics Inc.
  • Theracell Inc.
  • Thermogenesis Holdings
  • Vericel Corporation
  • Vistagen Therapeutics Inc.
  • Zelluna Immunotherapy Inc.
Note: Product cover images may vary from those shown
Adroll
adroll